Cellular accumulation and disposition of aclacinomycin A
- PMID: 498071
Cellular accumulation and disposition of aclacinomycin A
Abstract
The cellular accumulation and disposition of the anthracycline antitumor antibiotic aclacinomycin A (ACM) were compared to those of daunorubicin. Although both drugs were avidly accumulated by cells, intracellular concentrations of ACM were two to three times those of daunorubicin. Whereas lowered temperature (0 degrees) reduced intracellular accumulation of both drugs, 10 mM sodium azide had no effect on accumulation of either ACM or daunorubicin. Both drugs exited from cells placed in drug-free medium, a process that was reduced at 0 degrees but not altered by 10 mM sodium azide. Unlike whole cells, isolated nuclei accumulated more daunorubicin than ACM. This process was not altered at 0 degrees. Both drugs were lost from nuclei placed in drug-free buffer, a process that was reduced at 0 degrees. Unlike daunorubicin, which localized in cell nuclei, ACM localized in the cytoplasm with no detectable nuclear fluorescence. Although both drugs produced dose-dependent inhibitions of [3H]thymidine and [3H]uridine incorporation by L1210 and P388 cells, ACM inhibited both processes at lower concentrations than did daunorubicin. While daunorubicin inhibited [3H]thymidine incorporation more effectively than [3H]uridine incorporation, the reverse was observed with ACM.
Similar articles
-
Cellular pharmacology of 7(R)-O-methylnogarol: a new anticancer agent.J Pharmacol Exp Ther. 1979 Aug;210(2):229-36. J Pharmacol Exp Ther. 1979. PMID: 458629
-
Anthracycline resistance in P388 murine leukemia and its circumvention by calcium antagonists.Cancer Res. 1985 Apr;45(4):1687-91. Cancer Res. 1985. PMID: 3919944
-
Cellular pharmacology and antitumor activity of N-(p-azidobenzoyl)-daunorubicin, a photoactive anthracycline analogue.Cancer Chemother Pharmacol. 1986;16(3):211-7. doi: 10.1007/BF00293980. Cancer Chemother Pharmacol. 1986. PMID: 2421935
-
Experimental studies on aclacinomycin.Drugs Exp Clin Res. 1985;11(1):9-15. Drugs Exp Clin Res. 1985. PMID: 2424701 Review.
-
Aclacinomycin A: clinical development of a novel anthracycline antibiotic in the haematological cancers.Drugs Exp Clin Res. 1986;12(1-3):275-82. Drugs Exp Clin Res. 1986. PMID: 3525076 Review.
Cited by
-
Inhibition of protein kinases by anticancer DNA intercalator, 4-butylaminopyrimido[4',5':4,5]thieno(2,3-b)quinoline.Acta Pharm Sin B. 2017 May;7(3):303-310. doi: 10.1016/j.apsb.2017.01.001. Epub 2017 Mar 7. Acta Pharm Sin B. 2017. PMID: 28540166 Free PMC article.
-
The subcellular distribution of small molecules: from pharmacokinetics to synthetic biology.Mol Pharm. 2011 Oct 3;8(5):1619-28. doi: 10.1021/mp200092v. Epub 2011 Aug 15. Mol Pharm. 2011. PMID: 21805990 Free PMC article. Review.
-
Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines.Br J Cancer. 1993 Jun;67(6):1316-23. doi: 10.1038/bjc.1993.244. Br J Cancer. 1993. PMID: 8099807 Free PMC article.
-
Cellular pharmacokinetics of aclacinomycin A in cultured L1210 cells. Comparison with daunorubicin and doxorubicin.Cancer Chemother Pharmacol. 1982;8(2):243-9. doi: 10.1007/BF00255491. Cancer Chemother Pharmacol. 1982. PMID: 6955072
-
Salvage chemotherapy of refractory non-Hodgkin's lymphoma with aclacinomycin, behenoyl ara-C, etoposide, and prednisolone.Cancer Chemother Pharmacol. 1989;25(2):135-8. doi: 10.1007/BF00692354. Cancer Chemother Pharmacol. 1989. PMID: 2598400